- Home
- GTY vs GHRS Comparison
GTY vs GHRS Comparison
Compare GTY & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTY | GHRS |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTY | GHRS |
|---|---|---|
| Price | $28.63 | $18.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $33.86 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 469.7K | 303.0K |
| Earning Date | 10-21-2026 | 11-24-2026 |
| Dividend Yield | ★ 7.07% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $221,727,000.00 | N/A |
| Revenue This Year | $8.60 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | $23.96 | ★ N/A |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $27.08 | $12.04 |
| 52 Week High | $36.83 | $31.44 |
Technical Indicators
Market Signals| Indicator | GTY | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 41.39 |
| Support Level | $27.30 | $17.54 |
| Resistance Level | $28.90 | $22.51 |
| Average True Range (ATR) | 0.51 | 1.32 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 67.46 | 22.42 |
Price Performance
Historical ComparisonAbout GTY Getty Realty Corporation
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.